Thermedical, a privately held company developing proprietary thermal therapy equipment for numerous clinical conditions, announced that it closed $1.5 million in Series A funding with a private investor, Samuel H. Maslak, Sc.D. The financing will fund continued research and development, and additional patent filings; it will also help the company achieve 510(k) regulatory clearance from the U.S. Food & Drug Administration (FDA).

Thermedical is developing preclinical prototypes for a Saline-Enhanced Radio Frequency (SERF) ablation system for treating malignant solid tissue, such as liver cancer, and for difficult-to-treat cardiac arrhythmias, such as ventricular tachycardia (VT).